Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
AMSTERDAM, July 6, 2011 /PRNewswire/ –
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field
of human gene therapy, today announced the appointment of Dr. Carlos R.
Camozzi as Chief Medical Officer. Dr. Camozzi brings to AMT more than 25
years of pharmaceutical industry experience, most recently within the orphan
drug field. This includes overseeing product approvals at the European
Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).
“We are very fortunate to have attracted Carlos to AMT. He has joined
the company at a pivotal point as we continue to pursue the approval our
lead gene therapy Glybera with the EMA,” stated Jorn Aldag, CEO of AMT. “His
expertise in product development and related interaction with global
regulatory bodies in the orphan drug field will prove invaluable, not only
with Glybera, but also as we advance development of our gene therapy
Dr. Camozzi will join AMT on July 18 from Orphan Europe, where he held
the position of Medical Director for over 5 years. During his tenure, he
oversaw the approval of Carbaglu, a product for hyperammonemia in NAGS
deficiency and Organic Acidemias, with the EMA and FDA, EMEA marketing
authorisation renewals for two products, three orphan drug designations and
development of pediatric investigation plans. He was also responsible for
the clinical development in the pediatric field of orphan drugs in
therapeutic areas of metabolic disorders, immunology, dermatology,
cardiology and CNS.
Prior to Orphan Europe, Dr. Camozzi was a strategic development manager
in the Molecular Pathology department of Basel University Hospital, Basel,
Switzerland. In this role, he interacted with both pharmaceutical customers
and regulatory authorities. From 2001-2005, he was managing director of
MCP-medeor consulting pharma, where he helped design preclinical and
clinical development programs for pharmaceutical and healthcare products.
Dr. Camozzi started his career in South America holding roles at
Lederle/American Cyanamid and F Hoffmann La-Roche.
Dr. Camozzi earned his MD and PhD from the School of Medicine, National
University of Buenos Aires (Argentina), and holds degrees in Paediatrics,
Neonatology, Clinical Pharmacology and Neuropsychiatry.
About Amsterdam Molecular Therapeutics
AMT is a world leader in the development of human gene based therapies.
The company’s lead product Glybera(R), a gene therapy for lipoprotein lipase
deficiency (LPLD), is currently under review by the European Medicines
Agency (EMA). If approved, Glybera will be the first gene therapy product to
be marketed in Europe. AMT also has a product pipeline of several gene
therapy products in development for hemophilia B, Duchenne muscular
dystrophy, acute intermittent porphyria, Parkinson’s disease and
SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the
delivery vehicle of choice for therapeutic genes, the company has been able
to design and validate probably the world’s first stable and scalable AAV
manufacturing platform. This proprietary platform can be applied to a large
number of rare (orphan) diseases caused by one faulty gene and allows AMT to
pursue its strategy of focusing on this sector of the industry. AMT was
founded in 1998 and is based in Amsterdam. Further information can be found
Certain statements in this press release are “forward-looking
statements” including those that refer to management’s plans and
expectations for future operations, prospects and financial condition. Words
such as “strategy,”"expects,”"plans,”"anticipates,”"believes,”"will
,”"continues,”"estimates,”"intends,”"projects,”"goals,”"targets” and other
words of similar meaning are intended to identify such forward-looking
statements. Such statements are based on the current expectations of the
management of AMT only. Undue reliance should not be placed on these
statements because, by their nature, they are subject to known and unknown
risks and can be affected by factors that are beyond the control of AMT.
Actual results could differ materially from current expectations due to a
number of factors and uncertainties affecting AMT’s business. AMT expressly
disclaims any intent or obligation to update any forward-looking statements
herein except as required by law.
SOURCE Amsterdam Molecular Therapeutics B.V